Study design and participants
airflow obstruction, COPD
COPD
The CELEB study was a multicentre, randomised controlled, parallel-group superiority trial in which patients with COPD who were considered by a lung volume reduction multidisciplinary team (MDT) meeting to be suitable candidates for both forms of targeted lung reduction therapy, and who did not have collateral ventilation on Chartis assessment (PulmonX, Redwood City, CA, USA), were randomised to either BLVR or unilateral LVRS (Ethical approval was obtained from Fulham Research Ethics Committee (London, UK) (REC reference: 16/LO/0286). The trial protocol has been published previously [Participants were recruited at five UK hospital sites which had an established MDT meeting dedicated to identifying suitable candidates for lung volume reduction: Royal Brompton Hospital (London), Glenfield Hospital (Leicester), St Bartholomew's Hospital (London), Northern General Hospital (Sheffield) and Golden Jubilee National Hospital (Glasgow).Eligibility criteria: significant airflow obstruction (forced expiratory volume in 1 s (FEVExclusion criteria: smoked in previous 3 months [All participants were assumed to be medically optimised and required to have undergone a course of pulmonary rehabilitation within the 12 months preceding trial enrolment. The clinical MDT then decided on whether a patient was suitable for both interventions and if there was equipoise between the two options. It was only after this point in the normal clinical process that a trial screening visit was arranged and written informed consent was obtained.